Etoposide

Generic Name: Etoposide

Brand Names: Etopophos, Toposar, Vepesid

Drug Type: Small Molecule

Chemical Formula: C_₂₉H_₃₂O_₁₃

CAS Number: 33419-42-0

Unique Ingredient Identifier: 6PLQ3CP4P3

Background: A semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle.

Indication: For use in combination with other chemotherapeutic agents in the treatment of refractory testicular tumors and as first line treatment in patients with small cell lung cancer. Also used to treat other malignancies such as lymphoma, non-lymphocytic leukemia, and glioblastoma multiforme.

Associated Conditions: Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Advanced Hodgkin's Lymphoma, Ewing's Sarcoma, Gestational Trophoblastic Neoplasia, Merkel cell cancer, Multiple Myeloma (MM), Neuroblastoma (NB), Neuroendocrine Tumors, Non-Hodgkin's Lymphomas, Non-Small Cell Lung Cancer (NSCLC), Osteosarcoma, Ovarian Cancer, Prostate Cancer, Retinoblastoma, Small Cell Lung Cancer (SCLC), Wilms' tumor, Locally advanced Thymoma, Metastatic Thymic Cancer, Refractory Sarcoma, Refractory Testicular cancer

Associated Therapies: -

Clinical Trials

CHOEP + High Dose Therapy + Auto SCT for T-Cell Lymphoma

Phase 2

Terminated

Conditions: T-cell Non-Hodgkin Lymphoma

Interventions: Drug: Cyclophosphamide
Drug: Doxorubicin
Drug: Vincristine
Drug: Etoposide
Drug: Prednisone
Drug: Filgrastim
Drug: Plerixafor
Procedure: Stem Cell Collection
Drug: Palifermin
Drug: Gemcitabine
Drug: Busulfan
Drug: Melphalan
Procedure: Stem Cell Transplant

First Posted Date: 2012-12-10

Last Posted Date: 2023-01-30

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 5

Registration Number: NCT01746173

Locations: 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Decitabine Followed by Mitoxantrone Hydrochloride, Etoposide, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes

Phase 1

Completed

Conditions: Recurrent Adult Acute Myeloid Leukemia
Previously Treated Myelodysplastic Syndrome

Interventions: Drug: Cytarabine
Drug: Decitabine
Drug: Etoposide
Other: Laboratory Biomarker Analysis
Drug: Mitoxantrone Hydrochloride

First Posted Date: 2012-11-20

Last Posted Date: 2019-02-07

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 52

Registration Number: NCT01729845

Locations: 🇺🇸
Kadlec Clinic Hematology and Oncology, Kennewick, Washington, United States
🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
🇺🇸
EvergreenHealth Medical Center, Kirkland, Washington, United States

A Study of LY2940680 in Small Cell Lung Cancer

Phase 1

Terminated

Conditions: Small Cell Lung Carcinoma

Interventions: Drug: LY2940680
Drug: Carboplatin
Drug: Placebo
Drug: Etoposide

First Posted Date: 2012-11-06

Last Posted Date: 2018-12-28

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 26

Registration Number: NCT01722292

Locations: 🇺🇸
Mount Sinai Medical Center, New York, New York, United States
🇺🇸
Northwest Cancer Specialists PC, Vancouver, Washington, United States
🇬🇧
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Manchester, United Kingdom

and more 10 locations

High Risk Neuroblastoma Study 1.8 of SIOP-Europe (SIOPEN)

Phase 3

Recruiting

Conditions: Neuroblastoma

Interventions: Drug: ch14.18/CHO
Drug: Carboplatin
Drug: Vincristine
Drug: Busulfan
Drug: Aldesleukin
Drug: Etoposide
Drug: Melphalan
Drug: Cisplatin
Drug: Cyclophosphamide
Drug: G-CSF
Drug: Doxorubicin

First Posted Date: 2012-10-11

Last Posted Date: 2020-10-23

Lead Sponsor: St. Anna Kinderkrebsforschung

Target Recruit Count: 3300

Registration Number: NCT01704716

Locations: 🇵🇱
Medical University in Gdansk, Gdansk, Poland
🇵🇱
Children's University Hospital in Lublin, Lublin, Poland
🇵🇱
University of Medical Sciences Poznan, Poznan, Poland

and more 122 locations

Rituxan + BEAM and Auto Stem Cell Transplant for High Risk Lymphoma or Hodgkin's Disease

Not Applicable

Completed

Conditions: Hodgkin's Disease
Lymphoma

Interventions: Drug: Melphalan
Drug: Ara-C
Drug: VP-16
Drug: BCNU
Drug: Rituxan
Drug: Stem Cells

First Posted Date: 2012-10-10

Last Posted Date: 2018-12-19

Lead Sponsor: Baylor College of Medicine

Target Recruit Count: 75

Registration Number: NCT01702961

Locations: 🇺🇸
The Methodist Hospital, Houston, Texas, United States
🇺🇸
Texas Children's Hospital, Houston, Texas, United States

Therapy for Pediatric Relapsed or Refractory Precursor B-Cell Acute Lymphoblastic Leukemia and Lymphoma

Phase 2

Completed

Conditions: Recurrent B-Cell Childhood Acute Lymphoblastic Leukemia
Recurrent Childhood B-Lymphoblastic Lymphoma

Interventions: Drug: dexamethasone
Drug: vincristine sulfate
Biological: rituximab
Drug: clofarabine
Drug: cyclophosphamide
Drug: etoposide
Biological: aldesleukin
Drug: pegaspargase
Drug: methotrexate
Drug: mercaptopurine
Drug: cytarabine
Drug: mitoxantrone
Drug: teniposide
Drug: vinblastine
Biological: natural killer cell infusion
Other: laboratory biomarker analysis
Procedure: allogeneic hematopoietic stem cell transplantation
Drug: therapeutic hydrocortisone
Device: CliniMACS

First Posted Date: 2012-10-04

Last Posted Date: 2022-09-28

Lead Sponsor: St. Jude Children's Research Hospital

Target Recruit Count: 80

Registration Number: NCT01700946

Locations: 🇺🇸
Rady Children's Hospital and Health Center, San Diego, California, United States
🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States
🇺🇸
Cook Children's Medical Center, Fort Worth, Texas, United States

Lenalidomide Plus Chemotherapy for AML

Phase 1

Completed

Conditions: Acute Myelogenous Leukemia

Interventions: Drug: Lenalidomide
Drug: Mitoxantrone
Drug: Etoposide
Drug: Cytarabine

First Posted Date: 2012-09-10

Last Posted Date: 2016-03-17

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 36

Registration Number: NCT01681537

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States

Clofarabine, Cyclophosphamide and Etoposide for Minimal Residual Disease Positive Acute Leukemia

Phase 2

Withdrawn

Conditions: Acute Myeloid Leukemia
Acute Lymphoblastic Leukemia

Interventions: Drug: Clofarabine
Drug: Etoposide
Drug: Cyclophosphamide
Biological: allogeneic hematopoietic cell transplantation

First Posted Date: 2012-09-03

Last Posted Date: 2017-12-02

Lead Sponsor: Masonic Cancer Center, University of Minnesota

Registration Number: NCT01677949

Locations: 🇺🇸
Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States

Phase II Study of V-BEAM Conditioning Regimen Prior to Second Autologous Stem Cell Transplantation

Phase 2

Terminated

Conditions: Multiple Myeloma

Interventions: Drug: Bortezomib
Drug: Carmustine
Drug: Etoposide
Drug: Cytarabine
Drug: Melphalan
Procedure: Stem cell infusion

First Posted Date: 2012-07-31

Last Posted Date: 2014-10-15

Lead Sponsor: Washington University School of Medicine

Target Recruit Count: 10

Registration Number: NCT01653418

Locations: 🇺🇸
Washington University School of Medicine, St. Louis, Missouri, United States

Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung Cancer

Phase 1

Completed

Conditions: Extensive Stage Small Cell Lung Carcinoma
Large Cell Lung Carcinoma
Neuroendocrine Carcinoma
Small Cell Carcinoma
Stage IV Non-Small Cell Lung Cancer AJCC v7

Interventions: Drug: Cisplatin
Drug: Etoposide
Drug: Veliparib
Drug: Placebo

First Posted Date: 2012-07-17

Last Posted Date: 2023-05-06

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 156

Registration Number: NCT01642251

Locations: 🇺🇸
Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States
🇺🇸
Greenville Health System Cancer Institute-Easley, Easley, South Carolina, United States
🇺🇸
Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States

and more 423 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy